ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

RGNX REGENXBIO Inc

14.32
0.00 (0.00%)
Pre Mercado
Última actualización: 03:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
REGENXBIO Inc RGNX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 14.32 03:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
14.32
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/6/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202415:35EDGAR2Form 8-K - Current report
16/5/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202415:22EDGAR2Form 144 - Report of proposed sale of securities
10/5/202406:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08/5/202415:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202415:10EDGAR2Form 8-K - Current report
08/5/202415:05PRNUSREGENXBIO Reports First Quarter 2024 Financial Results and..
01/5/202406:05PRNUSREGENXBIO to Host Conference Call on May 8 to Discuss First..
24/4/202406:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
28/3/202406:05PRNUSREGENXBIO Announces Lancet Publication of Phase I/IIa Study..
27/3/202415:05PRNUSREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD..
11/3/202407:00EDGAR2Form 8-K - Current report
11/3/202406:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08/3/202405:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/3/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202405:03EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
06/3/202422:20PRNUSREGENXBIO Announces Pricing of Upsized Public Offering of..
06/3/202415:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/3/202415:10PRNUSREGENXBIO Announces Proposed Public Offering of Common Stock
05/3/202415:26EDGAR2Form 144 - Report of proposed sale of securities
05/3/202406:05PRNUSREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM..
29/2/202415:57PRNUSREGENXBIO to Host Webcast Event to Discuss New Interim..
27/2/202415:54EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202415:10EDGAR2Form 8-K - Current report
27/2/202415:05PRNUSREGENXBIO Reports Fourth Quarter and Full Year 2023..
21/2/202406:05PRNUSREGENXBIO to Host Conference Call on February 27 to Discuss..
16/2/202417:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202410:40PRNUSREGENXBIO Announces Pivotal Trial of RGX-121 for the..
07/2/202406:05PRNUSREGENXBIO Announces Completion of Enrollment in Cohort 2 and..
31/1/202406:05PRNUSREGENXBIO Announces Presentations at the 20th Annual..
18/1/202417:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202415:22EDGAR2Form 144 - Report of proposed sale of securities
16/1/202413:47PRNUSREGENXBIO Announces Positive Interim Data from Phase II..
10/1/202406:05PRNUSREGENXBIO Announces Presentation at the Hawaiian Eye and..
08/1/202406:05PRNUSU.S. District Court Issues Decision on REGENXBIO and..
04/1/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:21EDGAR2Form 144 - Report of proposed sale of securities
21/12/202312:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202315:29EDGAR2Form 144 - Report of proposed sale of securities
29/11/202306:05PRNUSREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE®..
08/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:10EDGAR2Form 8-K - Current report
08/11/202315:05PRNUSREGENXBIO Announces Updated Strategic Plans and Third..

Su Consulta Reciente

Delayed Upgrade Clock